Harmonization of antimicrobial susceptibility testing breakpoints in Europe: Implications for reporting intermediate susceptibility

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 183-185

  Brown, Derek ^a   MacGowan, Alasdair ^b  

^a Southmead Hospital ^*  (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

BSAC standard disc method; EUCAST; In vitro susceptibility testing

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM; DAPTOMYCIN; DORIPENEM; GENTAMICIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONSULTATION; DISK DIFFUSION; ENTEROBACTER; EUROPE; GERMANY; HEALTH SURVEY; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; NETHERLANDS; NONHUMAN; NORWAY; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; SWEDEN; URINARY TRACT INFECTION;

EID: 77950224947     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp432     Document Type: Article

References (23)

1. EUCAST 2002. EUCAST Procedure for Harmonising and Defining Breakpoints. http://www.srga.org/eucastwt/bpsetting.htm (25 August 2009, date last accessed).
2. EUCAST 2009. EUCAST Clinical Breakpoints. http://www.srga.org/eucastwt/MICTAB/index.html (25 August 2009, date last accessed).
3. EMEA 2007. Harmonisation of European Antimicrobial Susceptibility Testing Breakpoints Determined by EMEA/CHMP and EUCAST. www.emea.europa.eu/pdfs/human/sop/3043SOP.pdf (25 August 2009, date last accessed).
4. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA, USA, 2009.
5. Andrews JM. BSAC standardized disc susceptibility testing method. J Antimicrob Chemother 2001; 48 Suppl S1: 43-57.
6. BSAC Working Party on Antimicrobial Susceptibility Testing 2009. BSAC Methods for Antimicrobial Susceptibility Testing. http://www.bsac. org.uk/_db/_documents/Version_8_-_January_2009.pdf (25 August 2009, date last accessed).
7. BSAC 2009. BSAC Resistance Surveillance Website. http://www.bsacsurv. org/index.jsp?menutype=MainMenu&submenu=Y&parent=Home (25 August 2009, date last accessed).
8. Pearson CH, Whitehead JEM. Antibiotic sensitivity testing: a modification of the Stokes method using a rotary plater. J Clin Pathol 1974; 27: 430-1.
9. International Organization for Standardization (ISO). Clinical Laboratory Testing and In Vitro Diagnostic Test Systems. Susceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Test Devices. Part 1: Reference Method for Testing the In Vitro Activity of Antimicrobial Agents Against Rapidly Growing Aerobic Bacteria Involved in Infectious Diseases. International Standard 20776-1. Geneva, Switzerland: ISO, 2006.
10. MacGowan AP on behalf of the BSAC Working Parties on Resistance Surveillance. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 2008; 62 Suppl 2: ii105-14.
11. Mouton JW, Theuretzbacher U, Craig WA et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008; 61: 235-7.
12. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008; 52: 24-36.
13. Roberts JA, Boots R, Rickard CM et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007; 59: 285-91.
14. Lodise TP, Lomaestro B, Drusano G. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357-63.
15. Lorente L, Jimenez A, Martin MM et al. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009; 33: 464-8.
16. Hughes DW, Frei CR, Maxwell PR et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 2014-9.
17. MacGowan AP, Rogers CA, Holt HA et al. Activities of moxifloxacin against, and emergence or resistance in, Streptococcus pneumoniae and Pseudonomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003; 47: 1088-95.
18. MacGowan AP, Bowker KE. Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Straptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003; 47: 1096-100.
19. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
20. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. Clin Infect Dis 2008; 46: 193-200.
21. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519-27.
22. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis2002; 2: 231-42.
23. Paul M, Soares-Weiser K, Leibovici L. β-Lactam monotherapy versus β-lactam-aminoglycoside combination therapy for fever with neutropenia: a systematic review. BMJ 2003; 326: 1111-5